Notice of Intent to Publish a Funding Opportunity Announcement for Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)

Active
Yes
Status
Forecasted
Estimated Post Date
April 15th, 2024
Estimated Close Date
July 17th, 2024
Estimated Award Date
April 1st, 2025
Total Funding
$6,200,000.00
Award Ceiling
$750,000.00
Expected No. Awards
5
Opportunity No.
NOT-DK-24-017

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional). These centers are intended to support both basic and clinical research on Cystic Fibrosis (CF). The CF Research and Translation Centers provide shared resources to develop and test new therapies for CF and foster collaborations among institutions with a strong research base in CF. The funding opportunity will be available in April 2024, with an expected application due date in July 2024. The estimated total program funding is $6,200,000, and it is anticipated that five awards will be granted. The CF Research and Translation Centers play a crucial role in advancing CF research and improving treatments for individuals with CF.

Description

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for Cystic Fibrosis (CF) Research and Translation Centers. CF Research and Translation Centers are designed to support both basic and clinical research on Cystic Fibrosis. CF Research and Translation Centers support three primary research-related activities: Research Core services; a Pilot and Feasibility program; and an Administrative Core with an enrichment program. These CF Centers provide shared resources to support research to develop and test new therapies for CF and to foster collaborations among institutions with a strong existing research base in CF. The NIDDK currently supports seven CF Research and Translation Centers located at institutions with documented programs of research excellence in basic and clinical CF Research. Information about the currently funded CF Research and Translation Centers may be found at: https://www.niddk.nih.gov/research-funding/research-programs/cystic-fibrosis-research-translation-centers or https://www.cysticfibrosiscenters.org/. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.� The NOFO is expected to be published in April 2024 with an expected application due date in July 2024. This NOFO will utilize the P30 activity code. Details of the planned NOFO are provided below.

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)". This grant aims to support both basic and clinical research on Cystic Fibrosis (CF). CF Research and Translation Core Centers provide shared resources to develop and test new therapies for CF and foster collaborations among institutions with a strong research base in CF. The grant does not require cost sharing or matching. The funding instrument type is a grant, and the category of funding activity is health. The deadline for applications is July 17, 2024. The maximum award ceiling is $750,000. Other eligible applicants include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments, non-domestic entities, regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territories or Possessions. Non-domestic entities and components are not eligible to apply. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-010.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-010.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Notice of Intent to Publish a Notice of Funding Opportunity for Diabetes Research Centers (P30 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for Diabetes Research Centers (P30 Clinical Trial Optional). This initiative aims to solicit applications for research on diabetes, its complications, and related endocrine and metabolic diseases. The NOFO is expected to be published in Spring 2024, with an application due date in Summer 2024. The estimated total program funding is $7,500,000. The NOFO will utilize the P30 activity code. This opportunity falls under the category of Health and is a discretionary grant. The eligible applicants are others, and there is no cost sharing or matching requirement. The estimated synopsis post date is March 1, 2024, and the estimated synopsis close date is June 18, 2024. The estimated award date and project start date are both April 1, 2025.
Notice of Intent to Publish a Notice of Funding Opportunity for the Re-Issue of PAR-21-293 - Clinical and Translational Science Award (UM1 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) plans to reissue a Notice of Funding Opportunity (NOFO) for the Clinical and Translational Science Award (CTSA) Program hubs. This program aims to establish a collaborative consortium focused on advancing clinical and translational science (CTS) to bring more treatments to patients more quickly. The NOFO is expected to be published in Summer 2024, with an application due date in January 2025. The funding instrument type for this opportunity is a Cooperative Agreement. The estimated award date is December 16, 2025, and the estimated project start date is also December 16, 2025.
Notice of Intent to Publish a Funding Opportunity Announcement for Comprehensive Alcohol Research Centers (P60 Clinical trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for Comprehensive Alcohol Research Centers (P60 Clinical trial Optional). This opportunity aims to support interdisciplinary and collaborative research on Alcohol Use Disorder (AUD), alcohol misuse, alcohol-related problems, and other health-related consequences across the lifespan. The funding will be provided through a grant, and there is no cost sharing or matching requirement. The estimated synopsis post date is April 15, 2024, with an expected application due date in Fall 2024. The estimated award date is November 1, 2025, and the estimated project start date is January 1, 2026. The maximum award ceiling is $1,250,000. Eligible applicants include organizations and institutions other than the NIH. The opportunity falls under the category of Health and is considered discretionary. The opportunity will be published in Spring 2024, and further details will be provided in the Notice of Funding Opportunity (NOFO).